Global Respiratory Drugs Pipeline Analysis Market 2018–2024
- April, 2018
- Domain: Healthcare - Pharmaceuticals
Pages:
188
Tables:
88
Charts:
80
Regions/Countries:
Companies:
42
Enquiry Hours:
10
- Get Free 10% Customization in this Report
Overview: Pulmonary medicine is the branch of medical science that deals with diagnosis, prevention, and treatment of diseases affecting the respiratory system. Respiratory drugs finds its applications in Asthma, COPD, Cystic Fibrosis, Allergic Rhinitis and Others. Asthma is the major market share holder currently. The intensity of competition in the respiratory drug market is high with few players dominating the market. The high investments made in the development of respiratory drug delivery systems have favored the growth of the market. The entry of innovative and effective drugs in the market is expected to drive the future of the market.
Short-Acting Beta2-Agonists (SABA), Inhaled corticosteroids (ICS), anticholinergics, long-acting beta2-agonists (LABA), antihistamines, vasodilators, combination drugs, and others are the major respiratory dugs classes available in the market. Currently, primarily combination drugs drive the market, with top brands facing no real competition from generic alternatives. The emergence of inexpensive, state-of-the-art and effective drug delivery devices will provide stimulate the market growth.
Industry Trends
- GSK’s Adavir for Asthma and COPD remains as the top selling drug in the market, even on declined revenue in 2017
- Pharmaceutical companies in US are facing pricing pressure and launch of new respiratory drugs in the market are declining the sales of the blockbuster drugs in the market
- Cipla Ltd., a leader in the Indian market, announced in May 2017, that it planned to reduce the investment on the biosimilars, to increase their focus on the respiratory drugs due to the high profitability
More than 30 companies pipeline for the respiratory drugs is analyzed in the study. GlaxoSmithKline plc has the highest number of pipeline molecules in various clinical trials phases.
Benefits: The report provides complete details about the usage and adoption rate of respiratory drugs in various regions. With that, key stakeholders can know about the major trends, drivers, investments, and vertical player’s initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.
Key Stakeholders:
1 Industry Outlook
1.1 Industry Overview
1.1.1 Global Driver for Pharmaceutical Demand:
1.1.2 Pharmaceutical spending region wise
1.1.3 R&D pipeline in pharmaceutical industry
1.1.4 Top pharma drugs by sales in 2017 ($Million)
1.2 Industry Trends
1.3 Pest Analysis
2 Report Outline
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 Market Snapshot
3.1 Market Definition – Infoholic Research
3.2 Segment Addressable Market
3.1 Trends of Respiratory Drugs Market
4 Molecule Type: Analysis
4.1 Overview
5 Application: Analysis
5.1 Overview
5.2 Asthma
5.2.1 Key Takeaways
5.2.2 Company Analysis
5.3 Chronic Obstructive Pulmonary Disease (COPD)
5.3.1 Key Takeaways
5.3.2 Company Analysis
5.4 Cystic Fibrosis
5.4.1 Key Takeaways
5.4.2 Company Analysis
5.5 Lung Cancer
5.5.1 Key Takeaways
5.5.2 Company Analysis
5.6 Nasal Polyps
5.6.1 Key Takeaways
5.7 Idiopathic Pulmonary Fibrosis
5.7.1 Key Takeaways
5.7.2 Company Analysis
5.8 Others
6 Competitive Landscape
6.1.1 Company Analysis
7 Vendors Profile
7.1 AbbVie Inc.
7.1.1 Overview
7.1.2 Geographic Presence
7.1.3 Business Focus
7.1.4 SWOT Analysis
7.1.5 Business Strategies
7.2 Amgen Inc.
7.2.1 Overview
7.2.2 Geographic Presence
7.2.3 Business Focus
7.2.4 SWOT Analysis
7.2.5 Business Strategies
7.3 Astra Zeneca PLC
7.3.1 Overview
7.3.2 Geographic Presence
7.3.3 Business Focus
7.3.4 SWOT Analysis
7.3.5 Business Strategy
7.4 Bayer AG
7.4.1 Overview
7.4.2 Business Unit
7.4.3 Geographic Presence
7.4.4 Business Focus
7.4.5 SWOT Analysis
7.4.6 Business Strategy
7.5 Boehringer Ingelheim GmbH
7.5.1 Overview
7.5.2 Geographic Presence
7.5.3 Business Focus
7.5.4 SWOT Analysis
7.5.5 Business Strategy
7.6 Bristol-Myers Squibb
7.6.1 Overview
7.6.2 Geographic Presence
7.6.3 Business Focus
7.6.4 SWOT Analysis
7.6.5 Business Strategy
7.7 Celgene Corporation
7.7.1 Overview
7.7.2 Geographic Presence
7.7.3 Business Focus
7.7.4 SWOT Analysis
7.7.5 Business Strategy
7.8 Dr. Reddy’s Laboratories Limited
7.8.1 Overview
7.8.2 Business Unit
7.8.3 Geographic Presence
7.8.4 Business Focus
7.8.5 SWOT Analysis
7.8.6 Business Strategy
7.9 Eli Lilly & Company Ltd
7.9.1 Overview
7.9.2 Business Focus
7.9.3 SWOT Analysis
7.9.4 Business Strategies
7.10 F.Hoffmann-La Roche Ltd.
7.10.1 Overview
7.10.2 Business Unit
7.10.3 Geographic Presence
7.10.4 Business Focus
7.10.5 SWOT Analysis
7.10.6 Business Strategy
7.11 GlaxoSmithKline plc
7.11.1 Overview
7.11.2 Geographic Presence
7.11.3 Business Focus
7.11.4 SWOT Analysis
7.11.5 Business Strategy
7.12 Johnson & Johnson
7.12.1 Overview
7.12.2 Business Units
7.12.3 Geographic Revenue
7.12.4 Business Focus
7.12.5 SWOT Analysis
7.12.6 Business Strategies
7.13 Merck & Co., Inc.
7.13.1 Overview
7.13.2 Business units
7.13.3 Geographic Revenue
7.13.4 Business focus
7.13.5 SWOT analysis
7.13.6 Business strategies
7.14 Mylan N.V.
7.14.1 Overview
7.14.2 Geographic Presence
7.14.3 Business Focus
7.14.4 SWOT Analysis
7.14.5 Business Strategy
7.15 Novartis AG
7.15.1 Overview
7.15.2 Business Unit
7.15.3 Geographic Presence
7.15.4 Business Focus
7.15.5 SWOT Analysis
7.15.6 Business Strategy
7.16 Pfizer, Inc.,
7.16.1 Overview
7.16.2 Business Units
7.16.3 Geographic Presence
7.16.4 Business Focus
7.16.5 SWOT Analysis
7.16.6 Business Strategies
7.17 Sanofi
7.17.1 Overview
7.17.2 Geographic Presence
7.17.3 Business Focus
7.17.4 SWOT Analysis
7.17.5 Business Strategy
7.18 Teva Pharmaceutical Industries Ltd.
7.18.1 Overview
7.18.2 Business Unit
7.18.3 Geographic Presence
7.18.4 Business focus
7.18.5 SWOT analysis
7.18.6 Business Strategy
7.19 Vertex Pharmaceuticals Inc.
7.19.1 Overview
7.19.2 Geographic Presence
7.19.3 Business Focus
7.19.4 SWOT Analysis
7.19.5 Business Strategy
8 Companies to Watch For
8.1 FibroGen, Inc
8.1.1 Overview
8.1.2 Highlights
8.2 Gilead Sciences Inc.
8.2.1 Overview
8.2.2 Highlights:
8.3 Glenmark Pharmaceutical Ltd
8.3.1 Overview
8.4 Zia Labs
8.4.1 Overview
8.4.2 Zia Lab: Highlights
8.5 Vectura Group Plc
8.5.1 Overview
8.5.2 Vectura Group Plc: Highlights
8.6 Sosei Group Corporation
8.6.1 Overview
8.7 Almirall S.A.
8.7.1 Overview
8.8 Biogen Inc
8.8.1 Overview
8.9 CHIESI Farmaceutici SpA
8.9.1 Overview
8.9.2 CHIESI Farmaceutici SpA: Highlights
8.10 Takeda Pharmaceutical Co, Ltd
8.10.1 Overview
8.10.2 Highlights
8.11 Shionogi & Co., Ltd
8.11.1 Overview
8.11.2 Shionogi & Co., Ltd: Highlights
8.12 Sun Pharmaceuticals
8.12.1 Overview
8.12.2 Highlights
8.13 United Therapeutics Corp
8.13.1 Overview
8.13.2 Highlights
8.14 ProMetic Life Sciences Inc.
8.14.1 Overview
8.14.2 ProMetic Life Sciences Inc.: Highlights
8.15 Daiichi Sankyo, Inc.
8.15.1 Overview
8.15.2 Overview
8.16 Aurobindo Pharma Ltd
8.16.1 Overview
8.16.2 Aurobindo Pharma Ltd: Highlights
8.17 Eisai Co., Ltd
8.17.1 Overview
8.17.2 Eisai Co., Ltd: Highlights
8.18 Shire Plc
8.18.1 Overview
8.18.2 Shire Plc: Highlights
8.19 GNI Group Ltd
8.19.1 Overview
8.20 MediciNova, Inc
8.20.1 Overview
8.21 Ono Pharmaceutical Co., Ltd
8.21.1 Overview
8.22 Promedior, Inc
8.22.1 Overview
8.23 Sumitomo Dainippon Pharma Co., Ltd.
8.23.1 Overview
8.23.2 Sumitomo Dainippon Pharma Co., Ltd: Highlights
9 Annexure
Abbreviations
TABLE 1 MOLECULES IN PIPELINE FOR ASTHMA 27
TABLE 2 MOLECULES IN PIPELINE FOR CRONIC OBSTRUCTIVE PULMONARY DISORDER 33
TABLE 3 MOLECULES IN PIPELINE FOR CRONIC OBSTRUCTIVE PULMONARY DISORDER 37
TABLE 4 MOLECULES IN PIPELINE FOR LUNG CANCER 42
TABLE 5 MOLECULES IN PIPELINE FOR IDOPATHIC PULMONARY FIBROSIS 47
TABLE 6 MOLECULES IN PIPELINE FOR IDOPATHIC PULMONARY FIBROSIS 49
TABLE 7 ABBVIE INC.: OFFERINGS 56
TABLE 8 ABBVIE INC: RECENT DEVELOPMENTS 56
TABLE 9 AMGEN INC.: OFFERINGS 61
TABLE 10 AMGEN INC.: RECENT DEVELOPMENTS 61
TABLE 11 ASTRA ZENCA PLC: OFFERINGS 68
TABLE 12 ASTRA ZENCA PLC: RECENT DEVELOPMENTS 69
TABLE 13 BAYER AG: OFFERINGS 74
TABLE 14 BAYER AG: RECENT DEVELOPMENTS 74
TABLE 15 BOEHRINGER INGELHEIM GMBH: OFFERINGS 79
TABLE 16 BOEHRINGER INGELHEIM GMBH: RECENT DEVELOPMENTS 79
TABLE 17 BRISTOL-MYERS SQUIBB: OFFERINGS 84
TABLE 18 BRISTOL-MYERS SQUIBB: RECENT DEVELOPMENT 84
TABLE 19 CELGENE CORPORATION: OFFERINGS 90
TABLE 20 CELGENE CORPORATION: RECENT DEVELOPMENTS 90
TABLE 21 DR. REDDY’S LABORATORIES LIMITED: PRODUCT OFFERINGS 94
TABLE 22 DR. REDDY’S LABORATORIES LIMITED: RECENT DEVELOPMENTS 94
TABLE 23 ELI LILLY & COMPANY LTD.: PRODUCT OFFERINGS 102
TABLE 24 ELI LILLY & COMPANY LTD.: RECENT DEVELOPMENTS 102
TABLE 25 F. HOFFMANN-LA ROCHE LTD.: OFFERINGS 106
TABLE 26 F. HOFFMANN-LA ROCHE LTD.: RECENT DEVELOPMENTS 107
TABLE 27 GLAXOSMITHKLINE PLC: OFFERINGS 112
TABLE 28 GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS 113
TABLE 29 JOHNSON & JOHNSON: PRODUCT OFFERINGS 118
TABLE 30 JOHNSON & JOHNSON: RECENT DEVELOPMENTS 118
TABLE 31 MERCK & CO: PRODUCT OFFERINGS 125
TABLE 32 MERCK & CO: RECENT DEVELOPMENTS 125
TABLE 33 MYLAN N.V.: OFFERINGS 131
TABLE 34 MYLAN N.V.: RECENT DEVELOPMENT 131
TABLE 35 NOVARTIS AG: OFFERINGS 136
TABLE 36 NOVARTIS AG: RECENT DEVELOPMENTS 136
TABLE 37 PFIZER, INC.: OFFERINGS 141
TABLE 38 PFIZER, INC.: RECENT DEVELOPMENTS 142
TABLE 39 SANOFI: OFFERINGS 146
TABLE 40 SANOFI: RECENT DEVELOPMENTS 146
TABLE 41 TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCT OFFERINGS 151
TABLE 42 TEVA PHARMACEUTICAL INDUSTRIES LTD: RECENT DEVELOPMENTS 151
TABLE 43 VERTEX PHARMACEUTICALS INC.: OFFERINGS 156
TABLE 44 VERTEX PHARMACEUTICALS INC.: RECENT DEVELOPMENTS 156
TABLE 45 FIBROGEN, INC: OVERVIEW 161
TABLE 46 FIBROGEN INC: RECENT DEVELOPMENTS 161
TABLE 47 GILEAD SCIENCES INC.: OVERVIEW 162
TABLE 48 GILEAD SCIENCE INC: RECENT DEVELOPMENTS 162
TABLE 49 GLENMARK PHARMACEUTICAL LTD: OVERVIEW 164
TABLE 50 GLENMARK PHARMACEUTICAL LTD: RECENT DEVELOPMENTS 164
TABLE 51 ZIA LAB: OVERVIEW 165
TABLE 52 ZIA LAB: RECENT DEVELOPMENTS 165
TABLE 53 VECTURA GROUP PLC: OVERVIEW 166
TABLE 54 VECTURA GROUP AG: RECENT DEVELOPMENTS 166
TABLE 55 SOSEI GROUP CORPORATION: OVERVIEW 167
TABLE 56 SOSEI GROUP CORPORATION: RECENT DEVELOPMENTS 167
TABLE 57 ALMIRALL S.A: OVERVIEW 168
TABLE 58 ALMIRALL S.A.: RECENT DEVELOPMENTS 169
TABLE 59 BIOGEN INC: OVERVIEW 169
TABLE 60 BIOGEN INC: RECENT DEVELOPMENTS 170
TABLE 61 CHIESI FARMACEUTICI SPA: OVERVIEW 170
TABLE 62 CHIESI FARMACEUTICI SPA: RECENT DEVELOPMENTS 170
TABLE 63 TAKEDA PHARMACEUTICAL CO, LTD.: OVERVIEW 171
TABLE 64 TAKEDA PHARMACEUTICAL CO, LTD: RECENT DEVELOPMENTS 171
TABLE 65 SHIONOGI & CO., LTD: OVERVIEW 172
TABLE 66 SHIONOGI & CO., LTD: RECENT DEVELOPMENTS 172
TABLE 67 SUN PHARMACEUTICALS: OVERVIEW 173
TABLE 68 ZIA LAB: RECENT DEVELOPMENTS 174
TABLE 69 UNITED THERAPEUTICS CORP.: OVERVIEW 174
TABLE 70 PROMETIC LIFE SCIENCES INC.: OVERVIEW 175
TABLE 71 PROMETIC LIFE SCIENCES INC.: RECENT DEVELOPMENTS 176
TABLE 72 DAIICHI SANKYO, INC.: RECENT DEVELOPMENTS 176
TABLE 73 AUROBINDO PHARMA LTD: OVERVIEW 177
TABLE 74 AUROBINDO PHARMA LTD: RECENT DEVELOPMENTS 177
TABLE 75 EISAI CO., LTD: OVERVIEW 179
TABLE 76 EISAI CO., LTD: RECENT DEVELOPMENTS 179
TABLE 77 SHIRE PLC: OVERVIEW 180
TABLE 78 SHIRE PLC: RECENT DEVELOPMENTS 180
TABLE 79 GNI GROUP LTD: OVERVIEW 182
TABLE 80 GNI GROUP LTD: RECENT DEVELOPMENTS 182
TABLE 81 MEDICINOVA INC: OVERVIEW 183
TABLE 82 MEDICINOVA INC: RECENT DEVELOPMENTS 183
TABLE 83 ONO PHARMACEUTICAL CO., LTD: OVERVIEW 184
TABLE 84 ONO PHARMACEUTICAL CO., LTD: RECENT DEVELOPMENTS 184
TABLE 85 PROMEDIOR, INC: OVERVIEW 185
TABLE 86 PROMEDIOR INC: RECENT DEVELOPMENTS 185
TABLE 87 SUMITOMO DAINIPPON PHARMA CO., LTD: OVERVIEW 186
TABLE 88 SUMITOMO DAINIPPON PHARMA CO., LTD: RECENT DEVELOPMENTS 186
Research Framework
Infoholic Research works on a holistic 360° approach in order to deliver high quality, validated and reliable information in our market reports. The Market estimation and forecasting involves following steps:
- Data Collation (Primary & Secondary)
- In-house Estimation (Based on proprietary data bases and Models)
- Market Triangulation
- Forecasting
Market related information is congregated from both primary and secondary sources.
Primary sources
Involved participants from all global stakeholders such as Solution providers, service providers, Industry associations, thought leaders etc. across levels such as CXOs, VPs and managers. Plus, our in-house industry experts having decades of industry experience contribute their consulting and advisory services.
Secondary sources
Include public sources such as regulatory frameworks, government IT spending, government demographic indicators, industry association statistics, and company publications along with paid sources such as Factiva, OneSource, Bloomberg among others.
